Treatment
Asciminib clinical trials
We’re tracking 18 recruiting studies that include Asciminib, each written for real people, not researchers, below.
Recruiting studies
- NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Ramat GanAges 1–30 - NCT04877522RecruitingPhase 4
Continued asciminib treatment for certain leukemia patients
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Ann Arbor, MichiganAges 7–100 - NCT04925479RecruitingPhase 1/Phase 2
Testing asciminib dosing and safety for teen CML patients
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
Indianapolis, IndianaAges 1–17 - NCT07354074RecruitingPhase 2
Study of asciminib for children with Ph+ CML
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
New Brunswick, New JerseyAges 1–18 - NCT06684964Recruiting
Real-world study of asciminib for chronic CML in Saudi Arabia
This study is watching how well asciminib (Scemblix) works in real life for people with chronic-phase CML in Saudi Arabia. If you've already tried two or more targeted therapies (TKIs) and recently started asciminib, this study may help doctors understand more about its effectiveness and side effects.
DammamAges 18–99 - NCT07040982RecruitingPhase 1
Asciminib after cell therapy for Ph+ ALL
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
Duarte, CaliforniaAges 18 years+ - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT07250087RecruitingPhase 1
Asciminib maintenance after transplant or CAR T for Ph+ALL
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
Tampa, FloridaAges 18 years+ - NCT05943522Recruiting
Study of asciminib in adults with Ph+ CML on Scemblix
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
Wŏnju, Gangwon-doAges 18–100 - NCT06236724RecruitingPhase 2
Asciminib for newly diagnosed chronic myeloid leukemia
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Houston, TexasAges 18 years+ - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
The Bronx, New YorkAges 18 years+ - NCT06409936RecruitingPhase 2
Early use of asciminib for new CML patients
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
BarcelonaAges 18 years+ - NCT07549516Recruiting
Asciminib for Philadelphia chromosome-positive CML in chronic phase
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
Baden-Baden, Baden-WurttembergAges 18–100 - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Orange, CaliforniaAges 60 years+ - NCT06368414RecruitingPhase 2
Stopping TKI in CML after asciminib
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Incheon, IncheonAges 19 years+ - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99
What Asciminib is being studied for
Conditions with recruiting Asciminib studies.
Common questions
- Are there clinical trials studying Asciminib?
- Yes. Clin2 currently lists 18 recruiting studies that include Asciminib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Asciminib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Asciminib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Asciminib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.